The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
GE Healthcare Life Sciences To Build Biopharma Factory In China
GE Healthcare Life Sciences and biologics manufacturer JHL Biotech today announced that they will build a new biopharmaceutical factory in China.
Obesity Gene Affects Hip Fracture Risk
Australian researchers have demonstrated a strong association between the FTO (fat and obesity) gene and hip fracture in women.
French Horn Players Prone To Hearing Loss
A study has found that French horn players have among the highest risk of developing hearing loss among professional orchestral musicians.
‘Raspberry Particles’ As Sticky Tape For Water Droplets
Scientists have assembled rose petal-inspired 'raspberry particles' that act like sticky tape for water droplets.
Immune Cells Have A Role In Breast Cancer
A study by researchers in Australia has highlighted the important role played by immune cells in the risk of developing breast cancer.
Predictive Test For Obesity In Human Trials
Scientists in Australia are recruiting subjects for a trial to test if the stress hormone cortisol is a predictor of obesity.
MicroConstants China Licenses Liver Cancer Drug From Pertinax Therapeutics
MicroConstants China Inc. has licensed the China rights for a Phase II liver cancer drug candidate, PTX-9908, from Pertinax Therapeutics of Canada.
Servier, A*STAR To Develop Drugs That Target Immune System
French pharmaceutical company Servier has inked three Research Collaboration Agreements with A*STAR's Singapore Immunology Network.
Servier To License Lucitanib To SIMM In China
Servier and the Shanghai Institute of Materia Medica will collaborate on the development of lucitanib, a targeted antitumor drug candidate with anti-angiogenic effects, in China.